Myriad Genetics (MYGN) Announces Test Results Which Significantly Predict Biochemical Recurrence Risk After Prostatectomy
Up)
Myriad Genetics, Inc. (Nasdaq: MYGN) announced that a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," was presented on Thursday, February, 2, 2012 at the 2012 Genitourinary Cancers Symposium.
The study concluded that the Prolaris score, which analyzes the expression level of 46 cell cycle progression genes, demonstrated significant and unique prognostic ability in a contemporary cohort of men who had undergone radical prostatectomy, and accurately predicted their elevated risk for prostate cancer recurrence.
Researchers at the University of California, San Francisco, and Myriad, analyzed the Prolaris CCP score of 413 men's cancers from a contemporary cohort who had undergone radical prostatectomy. They found that the Prolaris test effectively stratified men by risk of biochemical recurrence. Specifically, 100% of patients in the study with low-risk Prolaris scores did not experience disease recurrence after five years. Prostate cancer did recur in 50% of the patients in the study with high-risk Prolaris scores.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The study concluded that the Prolaris score, which analyzes the expression level of 46 cell cycle progression genes, demonstrated significant and unique prognostic ability in a contemporary cohort of men who had undergone radical prostatectomy, and accurately predicted their elevated risk for prostate cancer recurrence.
Researchers at the University of California, San Francisco, and Myriad, analyzed the Prolaris CCP score of 413 men's cancers from a contemporary cohort who had undergone radical prostatectomy. They found that the Prolaris test effectively stratified men by risk of biochemical recurrence. Specifically, 100% of patients in the study with low-risk Prolaris scores did not experience disease recurrence after five years. Prostate cancer did recur in 50% of the patients in the study with high-risk Prolaris scores.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Myriad Genetics to Present at Upcoming Investor Conferences in June
- Orthofix (OFIX) Divests Sports Medicine Business Unit; Applies $145 Million to Debt
- Leerink Swann Upgrades Myriad Genetics (MYGN) to Outperform; Growth Prospects Good, Risks Overdone
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
